Alessandra Meddis

Alessandra Meddis

Auto-generated profile, based on publicly available information

Alessandra Meddis

Department of Biostatistics, University of Copenhagen , Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2019 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
LMLaura Marret
Laura Marret
AMAlessandra Meddis
Alessandra Meddis
LCLuc Cabel
Luc Cabel
CPCharlotte Proudhon
Charlotte Proudhon
ALAurelien Latouche
Aurelien Latouche
FBFrancois-Clement Bidard
Francois-Clement Bidard
Circulating tumor cells (CTCs) are particularly rare in non-metastatic breast cancer, and the clinical validity of CTC detection in that clinical setting was initially not well recognized. A cytological CTC detection device (CellSearch) fulfilling the CLIA requirements for analytical validity was subsequently developed and, in 2008, we reported the first study (REMAGUS02) showing that distant metastasis-free survival was shorter in early breast cancer patients with one or more CTCs. In the past 10 years, other clinical studies and meta-analyses have established CTC detection as a level-of-evidence 1 prognostic biomarker for local relapses, distant relapses, and overall survival. This review summarizes available data on CTC detection and the promises of this proliferation- and subtype-independent metastasis-associated biomarker in early breast cancer patients.

7 December 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MEMohamad El-Chouli
Mohamad El-Chouli
AMAlessandra Meddis
Alessandra Meddis
DCDaniel M Christensen
Daniel M Christensen
TGThomas A Gerds
Thomas A Gerds
TSThomas Sehested
Thomas Sehested
GGGunnar Gislason
Gunnar Gislason
Aims: In a continuously ageing population of patients with congenital heart disease (CHD), understanding the long-term risk of morbidity is crucial. The aim of this study was to compare the lifetime risks of developing comorbidities in patients with simple CHD and matched controls.Methods and results: Using the Danish nationwide registers spanning from 1977 to 2018, simple CHD cases were defined as isolated atrial septal defect (ASD), ventricular septal defect (VSD), pulmonary stenosis, or patent ductus arteriosus in patients surviving until at least 5 years of age. There were 10 controls identified per case. Reported were absolute lifetime risks and lifetime risk differences (between patients with simple CHD and controls) of incident comorbidities stratified by groups and specific cardiovascular comorbidities. Of the included 17 157 individuals with simple CHD, the largest subgroups were ASD (37.7%) and VSD (33.9%), and 52% were females. The median follow-up time for patients with CHD was 21.2 years (interquartile range: 9.4–39.0) and for controls, 19.8 years (9.0–37.0). The lifetime risks for the investigated comorbidities were higher and appeared overall at younger ages for simple CHD compared with controls, except for neoplasms and chronic kidney disease. The lifetime risk difference among the comorbidity groups was highest for neurological disease (male: 15.2%, female: 11.3%), pulmonary disease (male: 9.1%, female: 11.7%), and among the specific comorbidities for stroke (male: 18.9%, female: 11.4%). The overall risk of stroke in patients with simple CHD was mainly driven by ASD (male: 28.9%, female: 17.5%), while the risks of myocardial infarction and heart failure were driven by VSD. The associated lifetime risks of stroke, myocardial infarction, and heart failure in both sexes were smaller in invasively treated patients compared with untreated patients with simple CHD.Conclusion: Patients with simple CHD had increased lifetime risks of all comorbidities compared with matched controls, except for neoplasms and chronic kidney disease. These findings highlight the need for increased attention towards early management of comorbidity risk factors.

5 October 2023 in European Journal of Public Health
Verified
Journal Article
Open access
PDF file
PGPhilippe Grandjean
Philippe Grandjean
AMAlessandra Meddis
Alessandra Meddis
FNFlemming Nielsen
Flemming Nielsen
IBIben H Beck
Iben H Beck
NBNiels Bilenberg
Niels Bilenberg
EBEsben Budtz-Jørgensen
Esben Budtz-Jørgensen
Background: Fluoride may be a developmental neurotoxicant at elevated exposures. We merged new data from a prospective Odense Child Cohort (OCC) with results from two previous birth cohort studies from Mexico and Canada to characterize the dose–effect relationship in greater detail. Methods: The OCC contributed 837 mother–child pairs to the total of >1500. We measured creatinine-adjusted urine-fluoride concentrations in maternal urine samples obtained during late pregnancy. Child IQ was determined at age 7 years using an abbreviated version of the Wechsler Intelligence Scales for Children. Findings from the three cohorts were used to calculate the joint benchmark concentration (BMC) and the lower confidence limit (BMCL) after adjustment for covariables. Results: In the OCC, urine-fluoride concentrations varied between 0.08 and 3.04 mg/l (median 0.52 mg/l) but were not significantly associated with full-scale IQ at age 7 years (β = 0.08; 95% confidence interval −1.14 to 1.30 for a doubling in exposure). No difference was apparent between boys and girls. In the OCC, the BMC was 0.92 mg/l, with a BMCL of 0.30 mg/l. The joint analysis of all three cohorts showed a statistically significant association between urine-fluoride and IQ, with a BMC of 0.45 mg/l (BMCL, 0.28 mg/l), slightly higher than the BMC previously reported for the two North American cohorts alone. Conclusions: As the BMCL reflects an approximate threshold for developmental neurotoxicity, the results suggest that pregnant women and children may need protection against fluoride toxicity.

30 August 2020 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
AMAlessandra Meddis
Alessandra Meddis
PBPaul Blanche
Paul Blanche
FBFrançois C Bidard
François C Bidard
ALAurélien Latouche
Aurélien Latouche

9 December 2019 in Biometrical Journal
Verified
Journal Article
Closed access
PDF file
AMAlessandra Meddis
Alessandra Meddis
ALAurélien Latouche
Aurélien Latouche
BZBingqing Zhou
Bingqing Zhou
SMStefan Michiels
Stefan Michiels
JFJason Fine
Jason Fine

1 September 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SNSebastian Kinnberg Nielsen
Sebastian Kinnberg Nielsen
AMAlessandra Meddis
Alessandra Meddis
PBPaul Frédéric Blanche
Paul Frédéric Blanche
MHMads Hashiba
Mads Hashiba
MSMorten Schou
Morten Schou
MLMorten Kjøbek Lamberts
Morten Kjøbek Lamberts
Background: Despite growing initiatives to promote partially virtual care, there is still a lack of comprehensive data describing its use, patient characteristics, and medication management practices. Objective: This study aimed to examine the use of partially virtual care in the management of cardiovascular disease. Methods: We used nationwide Danish registries to identify all patients with a first-time diagnosis of atrial fibrillation (AF), heart failure (HF), pulmonary embolism (PE), or acute coronary syndrome (ACS) between 2019 and 2023. Patients were categorized as receiving partially virtual care if followed up at least once virtually or in-person care if seen solely in-person. We evaluated temporal changes in the use of partially virtual care and calculated the odds of receiving partially virtual care vs in-person care and the prevalence of initiating guideline-directed medical therapy (GDMT). For GDMT initiation, the exposure was instead the type of the patient’s first follow-up visit. Multivariable logistic regression was used to estimate the odds of receiving partially virtual care, adjusted for frailty score, residence, and period of diagnosis. Separate multivariable logistic regression models were then used to estimate adjusted average differences in the prevalence of GDMT initiation between virtual and in-person follow-up among patients not already on the medication, accounting for frailty score, residence, and period of diagnosis. Results: In total, 45,919 patients with AF, 30,482 with HF, 12,451 with PE, and 12,435 with ACS were followed up. Among these, 27.3% (AF: 12,517/45,919), 51.7% (HF: 15,749/30,482), 47.5% (PE: 5918/12,451), and 37.2% (ACS: 4627/12,435) had partially virtual follow-up. The use of partially virtual follow-up increased during the COVID-19 pandemic and remained high afterward. In 2023, 17.4% (475/2731) to 35.3% (876/2481) of patients’ first follow-up visits were virtual, depending on the condition. Patient-specific factors significantly associated with partially virtual care were patients residing in cities for those with AF (odds ratio [OR] 1.27, 95% CI 1.21‐1.34), HF (OR 1.38, 95% CI 1.31‐1.46), and PE (OR 1.14, 95% CI 1.04‐1.24), but not for patients with ACS, and “high frailty” for those with AF (OR 1.63, 95% CI 1.48‐1.80) and PE (OR 1.53, 95% CI 1.29‐1.81). A large percentage of patients were on GDMT prior to the first follow-up visit. Differences in new initiation of GDMT were small in absolute terms across conditions, regardless of virtual or in-person follow-up; for example, for patients with HF, 2.23% initiated sodium-glucose cotransporter-2 inhibitors following a virtual visit, vs 4.47% after an in-person visit (prevalence difference −2.24%, 95% CI, −2.61 to −1.87). Conclusions: Among patients who received follow-up, a considerable proportion of patients with cardiovascular disease (from 12,517/45,919, 27.3% to 15,749/30,482, 51.7%) received partially virtual care. The odds of receiving partially virtual care varied significantly based on patient characteristics, particularly place of residence and frailty score. Finally, small absolute differences were found in the initiation of new GDMT.